Communiqués Cantargia AB

Actions

CANTA

SE0006371126

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
1,360 ^SEK	-4,23%		-10,76%	-67,50%

30/09	Cantargia : l’association avec un inhibiteur de RAS a réduit la charge tumorale	FW
30/09	Cantargia AB met en avant des données précliniques présentées à l’AACR à l’appui de nadunolimab en association avec une inhibition de RAS dans l’ADCP	CI

Communiqués

30/09	Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDAC	AQ
10/09	Cantargia to Present at Investing in Life Science on September 22	AQ
31/08	Cantargia to Participate in Upcoming Investor Conferences	AQ
28/08	Cantargia to Participate in Upcoming Investor Conferences	AQ
28/08	Cantargia: Rasonque Approval Clears the Path to Phase Ib for Nadunolimab	AQ
20/08	Cantargia (Q2 Review): New Financing Locks In the PDAC Combination Study	AQ
19/08	Cantargia publishes Half-Year Report 2026	AQ
04/08	Cantargia to host Q2 2026 Interim Results Conference Call	AQ
31/07	Cantargia : Cantargia Announces Changes in Number of Shares and Votes	PU
31/07	Cantargia Announces Changes in Number of Shares and Votes	AQ
26/06	Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC	AQ
23/06	Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital	AQ
11/06	Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC	AQ
10/06	Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study	AQ
05/06	Cantargia publishes Information Document regarding Rights Issue of Shares	AQ
28/05	Cantargia AB to Host Webcast covering Rights Issue, Loan Agreement, and Strategic Priorities	AQ
28/05	Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million	AQ
21/05	Bulletin from the Annual General Meeting in Cantargia AB (publ)	AQ
21/05	Cantargia (Q1 Review): Shift Towards RAS Combination Strategy	AQ
19/05	Cantargia publishes interim report for the first quarter of 2026	AQ
06/05	Invitation to the Presentation of Cantargia's Interim Report for Q1 2026	AQ
06/05	Invitation to the Presentation of Cantargia’s Interim Report for Q1 2026	AQ
27/04	Cantargia Announces Early Results from Trial of nadunolimab in MDS and AML	AQ
17/04	Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC	AQ
17/04	Cantargia : Proposal regarding issue authorization	PU